Full-Time
Machine Technician 1
Posted on 8/21/2025
Merit Medical Systems
1,001-5,000 employees
Manufactures disposable medical devices for interventions
No salary listed
Company Does Not Provide H1B Sponsorship
South Jordan, UT, USA
In Person
 Mechanical Engineering (1) |
|---|
- Education equivalent to a High School Diploma with a minimum of one (1) year of relevant work experience.
- Demonstrates technical ability required to run automated processes with training.
- Demonstrates computer skills using required programs such as required by job.
- Ability to work well as a team member.
- Sets up and runs automated equipment.
- Performs and records test data necessary to verify the assembly / packaging process.
- Performs minor tooling changeovers under supervision and guidance.
- Cleans and resolves component feeding issues with equipment, as instructed.
- Performs other duties and tasks as required.
Merit Medical Systems develops, manufactures, and distributes proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures across cardiology, radiology, oncology, critical care, and endoscopy. These one-time-use devices are used during procedures and supported by a global sales force and clinical team that provides training and support to hospitals. The company differentiates itself with a broad, multi-specialty product portfolio, an international footprint for manufacturing and distribution, and strong customer service and clinical support. Its goal is to transform patient care by delivering medical solutions that meet hospitals’ and patients’ needs worldwide.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
South Jordan, Utah
Founded
1987
Simplify's Take
What believers are saying
- ViewPoint acquisition accretive by 2027 with OneMark sales projected to grow 20% annually.
- OEM segment recovery to mid-single-digit growth in Q2 2026 after Asia-Pacific destocking.
- Full-year 2026 guidance of 5.6% to 7.0% constant currency growth including $17-20M acquisitions.
What critics are saying
- ViewPoint dilutes 2026 non-GAAP EPS by $0.05 with only $2-4M initial revenue contribution.
- $15 million annual tariff assumption baked into guidance compresses gross margins permanently.
- China weakness and volume-based purchasing pressure stall international growth below 5% constant currency target.
What makes Merit Medical Systems unique
- Acquired ViewPoint Medical to triple oncology addressable market reach in breast cancer detection.
- Record first-quarter non-GAAP operating margin of 19.7% despite 120 basis point tariff headwind.
- Diversified portfolio across Cardiac, Endoscopy, and Oncology with integrated minimally invasive procedure solutions.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Paid Vacation
Paid Sick Leave
Paid Holidays
401(k) Retirement Plan
Health Savings Account/Flexible Spending Account
Flexible Work Hours
Company News
Merit Medical Systems has acquired View Point Medical for approximately $140 million, expanding its therapeutic oncology portfolio. The California-based company manufactures the OneMark Detection Imaging System and tissue markers for breast and soft tissue tumour localisation. Merit paid $90 million in cash at closing, with two deferred payments of $25 million each scheduled over the next two years. The acquisition targets an estimated 1.3 million biopsy procedures annually in the United States. View Point's ultrasound-enhanced technology will complement Merit's existing SCOUT platform, offering physicians more localisation options during diagnostic biopsies and potentially reducing the need for separate pre-surgery procedures. For 2026, the acquisition is projected to contribute $2 million to $4 million in revenue. Merit expects revenue of $14 million to $16 million in 2027, with OneMark sales growing at least 20% annually.
Medtronic has entered into a distribution agreement with Merit Medical Systems to offer the ViaVerte system, an FDA-cleared basivertebral nerve ablation treatment for chronic vertebrogenic lower back pain. The minimally invasive, implant-free system features a physician-controlled steerable mechanism for precise nerve targeting. ViaVerte, which will be available later this year, offers same-day outpatient procedures for patients suffering from chronic lower back pain caused by damaged vertebral endplates. According to the American Chronic Pain Association, one in three Americans suffer from chronic pain. The agreement expands Medtronic's pain interventions portfolio, which includes spinal cord stimulation, vertebral augmentation and targeted drug delivery. Merit Medical currently supplies Medtronic with inflation syringes and steerable balloon catheters for vertebral compression fracture treatments.
Merit Medical Systems has launched the Resilience Through-the-Scope Esophageal Stent in the US, designed to treat esophageal fistulas and strictures caused by malignant tumours. The stent features proprietary anti-migration flanges to prevent movement and is designed to demonstrate the greatest migration resistance amongst currently available TTS stents. A single-handed deployment system enables precise placement, whilst unique sizing options — 14mm x 50mm, 17mm x 50mm, and 20mm x 50mm — address various clinical needs unavailable elsewhere. Esophageal cancer is the sixth most common cause of cancer deaths globally. The new stent joins Merit's endoscopy portfolio, offering physicians enhanced control for treating patients experiencing difficulty swallowing, regurgitation and chest pain caused by esophageal narrowing.
Merit Medical Systems has faced pressure following a Wells Fargo downgrade and subsequent institutional selling, creating a disconnect between market sentiment and the company's fundamentals. The medical device supplier maintains solid operations despite the negative mood shift. Merit recently issued 2026 revenue guidance of $1.610 billion to $1.630 billion, implying mid-single-digit growth despite current headwinds including delayed WRAPSODY CIE reimbursement and higher operating expenses. The company's narrative projects $1.8 billion revenue and $197.2 million earnings by 2028, requiring 7% annual revenue growth. Key risks include continued weakness in China and volume-based purchasing pressure. Simply Wall St Community members currently value the stock between $82.26 and $103.55, suggesting potential upside of up to 48% from current levels.
Merit Medical Systems reported fourth-quarter 2025 adjusted earnings per share of $1.04, up 12% year over year and beating the Zacks Consensus Estimate by 8.3%. GAAP EPS was 63 cents, up 37% year over year. Fourth-quarter revenues reached $393.9 million, up 11% on a reported basis and topping the consensus estimate by 0.8%. At constant exchange rate, revenues increased 10%, with organic growth of 6.8%. For the full year, adjusted EPS improved 11% to $3.83, whilst total revenues rose 12% to $1.52 billion on a reported basis. US sales grew 11.6% to $238.2 million, and international sales increased 9.9% to $155.7 million. The Cardiovascular segment, which accounts for the majority of revenue, grew 11% to $373.9 million.